As your loved one’s care needs change, you must continually reevaluate your need for help as a care partner. As Parkinson’s disease (PD) advances, your needs might evolve from picking up groceries every now and then to hiring a home health aide for a few hours at a time.
Medical marijuana, or cannabis, is one of the most popular topics among the Parkinson’s disease (PD) community ― for people with PD, health professionals and researchers, alike. Earlier this year, the Parkinson’s Foundation hosted its first-ever convening on marijuana and Parkinson’s.
Parkinson’s disease (PD) results in the loss of dopamine-producing cells in the brain. Because dopamine cannot cross the blood-brain barrier (a safety feature of the brain), people cannot simply take dopamine pills. The drug levodopa (L-dopa) — a precursor to dopamine and the gold standard for treating PD — does have the ability to cross the blood-brain barrier, where it successfully converts into the much-needed dopamine.
Levodopa-induced dyskinesias (LIDs) are a debilitating side effect of long-term use of levodopa therapy that negatively impacts the quality of life for upwards of 90% of people with Parkinson’s disease (PD).
Over the next three years the Parkinson’s Foundation will invest more than $50 million to Parkinson’s disease (PD) research and clinical care. At the heart of our research initiatives are scientists and researchers who have received Foundation awards to improve our understanding of Parkinson’s, which will ultimately lead us to a cure.
People with Parkinson's disease (PD) experience major differences in their symptoms, responses to medications and side effects to treatments. Understanding genetic differences across people with Parkinson's can help uncover important clues about how and why each person's experience with PD differs.